Navigation Links
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
Date:3/14/2009

Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

(PRWEB) March 14, 2009 -- Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufacturing of all molecules under development at Med Discovery.

This strategic decision will allow Med Discovery SA to have priority access to Laborium Biopharma's clinical manufacturing capabilities and all related specialized services to ensure compliance of all its development projects to international regulations.

Dr. Deperthes President and CEO at Med Discovery S.A said: "In the upcoming months, Med Discovery will start the manufacturing of new biologics produced in mammalian cells. With this new extended agreement Med Discovery SA will accelerate the development of these innovative products allowing faster entry into pre-clinical and clinical phases. Validapro BioSciences Inc. will bring the operational flexibility and process development expertise to design value-added programs to meet Global cGMP expectations".

Luc Dubois President of Laborium Biopharma added: "In this difficult worldwide financial situation, such partnership agreement opens a new way to do business by sharing respective core competencies to reduce the risk associated with product development. That shall benefit both companies. Validapro BioSciences Inc. will be acting as the process development and clinical manufacturing arm allowing Med Discovery SA to focus at performing the R&D activities for those innovative compounds."

Med Discovery S.A. is a private biopharmaceutical company headquartered in Geneva, Switzerland focusing on treatments for uro-genital cancers. The company is dedicated to the discovery and the development of highly specific protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways. The company is leveraging a strong in-house expertise combined with an international network in clinical urology.

Laborium Biopharma is a private corporation based in the Biotechnology Research Institute of the National Research Council Canada in Montreal, Quebec. This new company is dedicated to the development and optimization of bio-production processes and the cGMP manufacturing of clinical batches of high-potency products.

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2228834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
3. European Centre for Modern Drug Discovery Established in Hamburg
4. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
5. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):